Ra Pharmaceuticals (NASDAQ:RARX) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.
Several other equities analysts also recently issued reports on RARX. Raymond James began coverage on shares of Ra Pharmaceuticals in a report on Thursday, June 28th. They set an “outperform” rating and a $18.00 price target for the company. ValuEngine downgraded shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Credit Suisse Group upped their price objective on shares of Ra Pharmaceuticals from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, August 7th. Zacks Investment Research downgraded shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, BMO Capital Markets initiated coverage on shares of Ra Pharmaceuticals in a report on Friday, July 20th. They issued an “outperform” rating and a $20.00 price objective for the company. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Ra Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.00.
Shares of RARX opened at $16.42 on Friday. Ra Pharmaceuticals has a 1 year low of $4.78 and a 1 year high of $19.43. The firm has a market cap of $585.03 million, a PE ratio of -6.81 and a beta of 1.42.
Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.01. Sell-side analysts expect that Ra Pharmaceuticals will post -2.14 EPS for the current year.
Hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC lifted its holdings in Ra Pharmaceuticals by 817.8% in the first quarter. Cubist Systematic Strategies LLC now owns 19,999 shares of the company’s stock worth $106,000 after purchasing an additional 17,820 shares during the period. Gabelli Funds LLC acquired a new stake in Ra Pharmaceuticals in the second quarter worth about $120,000. Dynamic Technology Lab Private Ltd acquired a new stake in Ra Pharmaceuticals in the first quarter worth about $128,000. Nisa Investment Advisors LLC acquired a new stake in Ra Pharmaceuticals in the second quarter worth about $157,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Ra Pharmaceuticals by 50.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 32,800 shares of the company’s stock worth $175,000 after purchasing an additional 11,000 shares during the period. 72.30% of the stock is owned by institutional investors and hedge funds.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Recommended Story: Discount Rate
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.